Search Filters

Search Results

Found 6 results

510(k) Data Aggregation

    K Number
    K163507
    Date Cleared
    2017-04-25

    (132 days)

    Product Code
    Regulation Number
    880.2750
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Gauss Surgical, Inc.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Triton Sponge System is a software application intended to be used as an adjunct in the estimation of blood loss and management of surgical sponges. The Triton Sponge System is intended to be used with surgical sponges, software, hardware and accessory devices which have been validated for use with the Triton Sponge System to estimate the hemoglobin (Hb) mass contained on used surgical sponges. The Triton Sponge System is also intended to calculate an estimate of blood volume on used surgical sponges from the estimated Hb mass and a user-entered patient serum Hb value. The validated surgical sponges, hardware, software, accessory devices and Hb mass ranges are listed in the Instructions for Use. The Triton Sponge System is also indicated for use to aid in counting surgical sponges and may be used to record and display case-specific blood components infused over time. The Triton Sponge System is additionally indicated for use to aid in managing surgical sponges, including providing a visual record of sponge images, and to record the user-entered weight of used surgical sponges in order to calculate an estimate of fluid volume on the sponges.

    Device Description

    The Triton Sponge System is a software application intended to be used as an adjunct in the estimation of blood loss and management of surgical sponges. The Triton Sponge System is intended to be used with surgical sponges, software, hardware and accessory devices which have been validated for use with Triton Sponge System to estimate the hemoglobin (Hb) mass contained on used surgical sponges. This version of the Triton Sponge System includes 4 updates from the predicate Triton System (K160338): Qualified new hardware accessory: Apple's iPad Pro to be used with Triton Sponge System. Qualified new accessory for imaging sponges: Users will use a commercially available 3D IR laser depth sensor (referred to as the Natural User Interface or NUI Sensor in the submission) that allows for automatic detection of sponges as well as a touch-free interface with the device to facilitate imaging of the sponge on Apple's iPad Pro device. To allow the use of the NUI Sensor with the Triton Sponge System, a new algorithm called the Sponge Recognition Algorithm (SRA) was added to the System. The SRA analyzes the depth maps provided by the NUI Sensor to determine whether or not a User is presenting a sponge for imaging. To allow the NUI Sensor to securely connect to the iPad Pro, NUI mounting brackets are provided to connect the NUI Sensor to the iPad Pro. Addition of a step to include imaging a calibration placard with Triton Sponge App to normalize ambient light settings. The calibration card is provided to standardize the image of each sponge. Updates to the Hemoglobin Algorithm to improve hemoglobin mass estimates by performing scene normalization as well as utilizing new data provided by the calibration palette and NUI Sensor.

    AI/ML Overview

    The provided text describes the Triton Sponge System, a software application intended to be used as an adjunct in the estimation of blood loss and management of surgical sponges. It explains the acceptance criteria for this device and the studies conducted to prove it meets these criteria.


    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are derived from the "Special Controls Required for 21 CFR §880.2750" (Table 6-1 on page 14). The device performance is summarized from the "Special Control Met" column and the "PERFORMANCE DATA" section (pages 10-14).

    Special Control Required (Acceptance Criteria)Reported Device Performance
    1. Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. Demonstration of the performance characteristics must include a comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass. The following use conditions must be tested: A. Lighting conditions; B. Range of expected hemoglobin concentrations; C. Range of expected blood volume absorption; and D. Presence of other non-sanguineous fluids (e.g., saline irrigation fluid)Non-clinical performance testing using the iPad Pro and the NUI sensor was conducted and demonstrated that the device performs as intended under anticipated conditions of use including expected lighting conditions, range of expected hemoglobin values, range of expected blood volume absorption and presence of other non-sanguineous fluids. A strong positive linear correlation and acceptable agreement via Bland-Altman analysis were found between Triton sHbL and Assay sHbL.
    2. Human factors testing and analysis must validate that the device design and labeling are sufficient for appropriate use by intended users of the device.Human factors testing and analysis demonstrated that the Triton Sponge System, labeling, and the NUI sensor as an accessory to support scanning of images with the Triton Sponge System are sufficient for appropriate use by intended users of the Triton Sponge System. All users successfully completed tasks per protocol pass/fail criteria in a simulated setting.
    3. Appropriate analysis and non-clinical testing must validate the electromagnetic compatibility (EMC) and wireless performance of the device.EMC and wireless performance of the Triton Sponge System with new iPad Pro and accessory NUI Sensor have been validated against IEC 60601-1-2:2007. The iPad Pro maintained essential wireless functionality under all test conditions.
    4. Appropriate software verification, validation and hazard analysis must be performed.Software verification, validation and hazard analysis have been performed. Software verification demonstrated that all specified requirements, including hazard mitigations, have been fulfilled. Validation testing demonstrated that all device specifications conform with user needs and intended uses.
    5. Software display must include an estimate of the cumulative error associated with estimated blood loss values.An estimate of the cumulative error associated with blood loss values is displayed to the user with each estimated hemoglobin mass and blood loss value. This is informed by Bland-Altman methods from verification testing.
    6. Labeling must include: A. Warnings, cautions, and limitations needed for safe use of the device; B. A detailed summary of the performance testing pertinent to use of the device, including a description of the bias and variance the device exhibited during testing; C. The validated surgical materials, range of hemoglobin mass, software, hardware, and accessories that the device is intended to be used with; and D. EMC and wireless technology instructions and information.Labeling includes all details as required by the special controls. This includes prescription statement, warnings, cautions, limitations, performance testing summary (bias and variance), validated materials/ranges/hardware/accessories, and EMC/wireless information.

    2. Sample Size Used for the Test Set and the Data Provenance

    • Sample Size for performance testing (bench-top and system validation): The document states "Testing involved running the software app/system test protocol with sample specimens" for bench testing and for system validation, it used "mock surgical case simulated by reconstituting whole blood samples of known Hb concentration from units of human packed red blood cells and plasma to create various pre-specified blood volumes. Serial dilution with sterile saline yielded sponge blood samples reconstituted to ranges of fluid volume, dilution, and Hb mass representative of a surgical operation."
      • The exact number of "sample specimens" or "blood volumes" / "dilution levels" is not explicitly stated in the provided text.
    • Data Provenance: The data used for performance testing (bench-top and system validation) appears to be prospective and simulated in a laboratory/mock surgical setting. The blood samples were "reconstituted" and "serial dilution with sterile saline" was performed. There is no indication of patient data or data from a specific country of origin, suggesting it's synthetic or laboratory-generated.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

    The ground truth for the performance tests (bench and system validation) was established using "pre-measured Hb mass (Assay sHbL)" of the samples. This indicates a direct quantitative measurement rather than expert interpretation.

    • Therefore, no experts were used to establish the ground truth in the traditional sense of clinical assessment (e.g., radiologists, pathologists). The ground truth was based on laboratory assay measurements.
    • The qualifications of individuals performing these assays are not specified, but it's implied to be standard laboratory practice for measuring hemoglobin mass.

    4. Adjudication Method for the Test Set

    Since the ground truth for performance testing was based on pre-measured laboratory assays, there was no adjudication method involving multiple human readers or experts. The comparison was directly between the device's output and the established objective measurement.


    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

    No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted involving human readers with and without AI assistance to measure effect size. The studies described are primarily technical performance validation (accuracy of Hb estimation) and human factors usability of the device itself.


    6. If a Standalone (i.e. algorithm only without human-in-the loop performance) Was Done

    Yes, standalone performance testing was done for the algorithm's core function. The bench-top and system validation tests evaluated the algorithm's ability to estimate hemoglobin mass (sHbL) from imaged sponges by comparing "Triton sHbL" (algorithm output) to "Assay sHbL" (pre-measured ground truth).

    • The process involved the App capturing images, transferring them to a server-based hemoglobin algorithm software, which then calculated the Triton sHbL. This calculated value was then compared to the Assay sHbL. This effectively represents the algorithm's standalone performance in estimating Hb mass from image input.

    7. The Type of Ground Truth Used

    The type of ground truth used for the quantitative performance studies (bench-top and system validation) was objective laboratory measurement of hemoglobin mass, referred to as "pre-measured Hb mass (Assay sHbL)". This involved depositing known quantities of blood with known Hb mass on surgical sponges.


    8. The Sample Size for the Training Set

    The document does not explicitly state the sample size for the training set used to develop or refine the Hemoglobin Algorithm, nor does it specify if a separate training set was used for the Sponge Recognition Algorithm (SRA). The text focuses on the testing and validation of the device.


    9. How the Ground Truth for the Training Set Was Established

    The document does not provide information on how the ground truth for any training set was established. It primarily details the methods for creating test data and establishing ground truth for validation purposes.

    Ask a Question

    Ask a specific question about this device

    K Number
    K160338
    Device Name
    Triton System
    Date Cleared
    2016-08-05

    (179 days)

    Product Code
    Regulation Number
    880.2750
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    GAUSS SURGICAL INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Triton System is a software application intended to be used as an adjunct in the estimation of blood loss and management of surgical sponges.

    The Triton System is intended to be used with surgical sponges, software and accessory devices which have been validated for use with the Triton System to estimate the hemoglobin (Hb) mass contained on used surgical sponges. The Triton System is also intended to calculate an estimate of blood volume on used surgical sponges from the estimated Hb mass and a user-entered patient serum Hb value. The validated surgical sponges, hardware, accessory devices and Hb mass ranges are listed in the Instructions for Use.

    The Triton System is also indicated for use to aid in counting surgical sponges and may be used to record and display case-specific blood components infused over time. The Triton System is additionally indicated for use to aid in managing surgical sponges, including providing a visual record of sponge images, and to record the user-entered weight of used surgical sponges in order to calculate an estimate of fluid volume on the sponges.

    Device Description

    The Triton System is a software program (mobile medical application) used on an Apple iPad® tablet to capture images of used surgical sponges to assist surgical personnel in the management of surgical sponges after surgical use and to aid in the estimation of blood loss.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study information for the Triton System, based on the provided document:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance Criteria (Special Control)Reported Device Performance
    1. Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. Demonstration of the performance characteristics must include a comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass. The following use conditions must be tested: A. Lighting conditions; B. Range of expected hemoglobin concentrations; C. Range of expected blood volume absorption; and D. Presence of other non-sanguineous fluids (e.g., saline irrigation fluid)"There is no change to the performance data of the product with the device modifications subject to this submission. Therefore previous non clinical testing validate that device performs as intended under anticipated conditions of use." (Implies previous testing met this, and current submission does not introduce new performance change necessitating re-testing)
    2. Human factors testing and analysis must validate that the device design and labeling are sufficient for appropriate use by intended users of the device."Human factors testing and analysis validate the device design and labeling are appropriate for use by intended users of device."
    3. Appropriate analysis and non-clinical testing must validate the electromagnetic compatibility (EMC) and wireless performance of the device."No modifications made to the device that would change EMC compatibility or wireless performance of device." (Implies previous testing for EMC and wireless performance remains valid)
    4. Appropriate software verification, validation and hazard analysis must be performed."Software verification and hazard analysis was performed."
    5. Software display must include an estimate of the cumulative error associated with estimated blood loss values."An estimate of the cumulative error associated with blood loss values is displayed to the user with each estimated hemoglobin mass and blood loss value. The Bland-Altman methods inform the look-up tables and resultant values displayed on the user interface each time the Triton System is used for the estimation of hemoglobin mass and blood volume loss."
    6. Labeling must include: A. Warnings, cautions, and limitations needed for safe use of the device; B. A detailed summary of the performance testing pertinent to use of the device, including a description of the bias and variance the device exhibited during testing; C. The validated surgical materials, range of hemoglobin mass, software, hardware, and accessories that the device is intended to be used with; and D. EMC and wireless technology instructions, information, and precautions."Labeling includes all details as required by the special controls."

    2. Sample Size Used for the Test Set and Data Provenance

    The provided document does not specify the sample size used for the test set. It mentions "previous non clinical testing" for the performance criteria and verification testing for the current submission, but lacks details on the number of cases or samples.

    The data provenance is not explicitly stated (e.g., country of origin). However, given that Gauss Surgical Inc. is located in Los Altos, California, USA, and this is an FDA submission, it's highly probable that the studies were conducted in the United States. The document does not specify if the data was retrospective or prospective.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

    The document does not provide information regarding the number of experts used to establish the ground truth for the test set or their qualifications.

    4. Adjudication Method for the Test Set

    The document does not specify an adjudication method.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done

    The document does not mention a multi-reader, multi-case (MRMC) comparative effectiveness study. The submission focuses on comparing the Triton System to a predicate device (Pixel 3 System) based on technological characteristics and indications for use, rather than human reader performance with and without AI assistance.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    The document describes the Triton System as a "software application intended to be used as an adjunct in the estimation of blood loss." This implies that it's designed to assist human users, rather than being a fully standalone diagnostic tool replacing human expertise. The performance data mentioned largely relates to the device's ability to measure hemoglobin mass and blood volume, which is a standalone function of the algorithm itself, to then be used by clinicians. However, no specific "standalone" study separate from its "adjunct" role is detailed. The focus is on the algorithm's accuracy in its intended use.

    7. The Type of Ground Truth Used

    The document mentions that the non-clinical performance data involved "comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass." This indicates that the ground truth for blood loss estimation (specifically hemoglobin mass) was established using a scientifically valid, presumably quantitative, laboratory or reference method rather than expert consensus, pathology, or outcomes data in this context. While not explicitly named, it would likely be a gold standard measurement for hemoglobin.

    8. The Sample Size for the Training Set

    The document does not provide the sample size for the training set.

    9. How the Ground Truth for the Training Set was Established

    The document does not explicitly detail how the ground truth for the training set was established. It implicitly suggests that the ground truth for hemoglobin mass would be established through a "scientifically valid alternative method" as mentioned for the performance testing.

    Ask a Question

    Ask a specific question about this device

    K Number
    K142801
    Date Cleared
    2015-03-12

    (164 days)

    Product Code
    Regulation Number
    880.2750
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Applicant Name (Manufacturer) :

    Gauss Surgical, Inc.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Triton Canister System is a software application intended to be used as an adjunct in the estimation of blood loss.

    The Triton Canister System is intended to be used with blood bearing canisters, software, hardware, and accessory items which have been validated for use with the Triton Canister System to estimate the hemoglobin (Hb) mass contained within canisters with the input of the total volume in each canister. The Triton Canister System is also intended to calculate an estimate of blood volume in blood bearing canisters from the estimated Hb mass and a user-entered patient serum Hb value. The validated canister types, hardware, software, accessory devices, and Hb mass ranges are listed in the Instructions for Use.

    Device Description

    The Gauss Surgical Triton Canister System is an image processing system to estimate the external blood lost from patients into a suction canister used to collect fluid during surgical procedures. The system is comprised of the software which runs on a mobile platform (Apple® iPad®) and two accessories provided by Gauss Surgical, a Canister Type Specific Insert and a Canister Scanning Label. The Insert and Label ensure variables associated with imaging are standardized.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the Triton Canister System:

    Acceptance Criteria and Device Performance

    The general acceptance criteria for "Non-clinical performance data" is that the device performs as intended under anticipated conditions of use, with a comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass. Specific conditions tested include:

    • Lighting conditions
    • Range of expected hemoglobin concentrations (and hemolysis levels)
    • Range of expected blood volume absorption in canisters
    • Presence of other non-sanguineous fluids (e.g., saline irrigation fluid)

    The study employed Bland-Altman analysis to establish the bias and limits of agreement between the device's estimated hemoglobin mass (Triton cHbL) and the pre-measured hemoglobin mass (Assay cHbL).

    Acceptance Criteria CategorySpecific CriteriaReported Device Performance and Methodology
    Non-clinical performance data (Accuracy)Device performs as intended under anticipated conditions of use, showing a comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass. This includes testing:
    A. Lighting conditions
    B. Range of expected hemoglobin concentrations
    C. Range of expected blood volume absorption
    D. Presence of other non-sanguineous fluids (e.g., saline irrigation fluid)Verification and Validation Bench Testing:
    • Deposited known quantities of blood volume and Hb mass into canisters.
    • Canister fluid samples represented clinically-expected ranges and distributions of fluid volume, dilution (by saline), Hb mass, hemolysis levels, ambient light illuminance, and serum patient Hb.
    • Triton Canister App used to capture scans under three different ambient lighting conditions.
    • User-entered volumes were recorded.
    • Images and volumes transferred to server-based software to calculate Triton cHbL.
    • cHbL compared to pre-measured Hb mass (Assay cHbL).
    • Result: Strong positive linear correlation between Triton cHbL and Assay cHbL across tested conditions.
    • Result: Bias and outer 95% CIs of the Bland-Altman Limits of Agreement fell within pre-determined acceptance criteria.
    • This testing informed look-up tables and "error estimate" values displayed on the user interface. |
      | Software display of cumulative error | Software display must include an estimate of the cumulative error associated with estimated blood loss values. | Met: An estimate of the cumulative error associated with blood loss values is displayed to the user with each estimated hemoglobin mass and blood loss value. The results of verification testing and Bland-Altman methods inform these displayed values. |
      | Human factors testing and analysis | Validate that the device design and labeling are sufficient for appropriate use by intended users of the device. | Met: A usability study was conducted in a simulated setting with personnel who track blood loss during surgical procedures. Both quantitative and qualitative survey data were collected. All users successfully completed tasks per protocol pass/fail criteria. |
      | Electromagnetic Compatibility (EMC) and wireless performance | Appropriate analysis and non-clinical testing must validate the EMC and wireless performance of the device. | Met: EMC and wireless coexistence testing completed for the predicate device (Pixel 3 System) using the same iPad 2 was reviewed. The iPad 2 was found to be EMC compatible with the operating room environment (Class B requirements of IEC 60601-1-2:2007) and maintained essential wireless functionality under noisy conditions. |
      | Software verification, validation, and hazard analysis | Appropriate software verification, validation and hazard analysis must be performed. | Met: Software is considered a moderate level of concern. All elements of software information for moderate LOC devices (per FDA Guidance May 11, 2005) were provided, including development program, hazard analysis (patient's and user's standpoint), validation process, system-level test protocols, pass/fail criteria, results, and cybersecurity risk mitigation. Testing demonstrated software performs as intended and risks are mitigated. |
      | Labeling | Labeling must include:
      A. Warnings, cautions, and limitations for safe use;
      B. Detailed summary of performance testing pertinent to use, including bias and variance;
      C. Validated surgical materials, range of hemoglobin mass, software, hardware, and accessories;
      D. EMC and wireless technology instructions and information. | Met: Labeling includes all required details from the special controls. |

    Study Details for Performance Testing Bench

    1. Sample Size used for the test set and the data provenance:

      • The document states, "Whole blood samples of known Hb concentration and various pre-specified volumes were reconstituted from units of human packed red blood cells and plasma." It also mentions, "Serial dilution yielded canister samples reconstituted to ranges of fluid volume, dilution, hemolysis levels and Hb mass."
      • The exact numerical sample size for the test set (number of canisters/samples) is not explicitly stated in the provided text.
      • Data Provenance: The blood samples were reconstituted from units of human packed red blood cells and plasma. The testing was retrospective in nature, as it involved preparing samples with known characteristics in a lab setting ("bench testing") rather than collecting data from live surgical procedures. The country of origin for the data is not specified, but given it's an FDA submission, it's highly likely to be within the United States.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience):

      • The ground truth for the test set was established by "pre-measured Hb mass (Assay cHbL)" of the reconstituted samples. This implies a laboratory assay was used, which would typically be performed by trained lab technicians or scientists.
      • The document does not specify the number or qualifications of individuals who established this ground truth, beyond referencing the "scientifically valid alternative method" of laboratory assay.
    3. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

      • The ground truth was established by direct measurement (Assay cHbL) rather than expert consensus on interpretive data. Therefore, an adjudication method for human readers is not applicable in this context.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No, an MRMC comparative effectiveness study was not done. This study focuses on the standalone performance of the device in estimating hemoglobin mass in canisters, not on human reader performance with or without AI assistance. The device is described as "an adjunct in the estimation of blood loss," implying it provides data to clinicians, rather than directly assisting in the interpretation of images by human readers in a diagnostic setting.
    5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Yes, a standalone performance study was done for the algorithm. The "Performance Testing Bench" described the "ability of the Triton Canister System (including algorithm, app, server and accessories – Insert and Scanning Label) to estimate canister hemoglobin mass loss and canister blood volume loss in comparison to a scientifically valid method of estimating hemoglobin mass and blood volume contained in canisters." The algorithm calculated the "Triton cHbL" which was then compared to the "Assay cHbL." While a user-entered volume is an input, the core estimation of Hb mass from the image is an algorithmic, standalone function.
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • The ground truth used was laboratory assay / direct measurement of hemoglobin mass ("Assay cHbL") in the prepared samples. This is a highly objective, quantitative form of ground truth.
    7. The sample size for the training set:

      • The document does not explicitly state the sample size used for the training set for the Triton Canister System's algorithm. It describes the testing of the performance of the algorithm.
    8. How the ground truth for the training set was established:

      • The document does not explicitly describe how the ground truth for the training set was established. However, given the nature of the device and the performance testing, it is highly probable that the training data would also utilize laboratory-measured hemoglobin mass in similar prepared samples, just like the test set.
    Ask a Question

    Ask a specific question about this device

    K Number
    DEN130015
    Device Name
    PIXEL 3 SYSTEM
    Date Cleared
    2014-05-09

    (459 days)

    Product Code
    Regulation Number
    880.2750
    Type
    Direct
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Applicant Name (Manufacturer) :

    GAUSS SURGICAL, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Pixel 3 System is a software application intended to be used as an adjunct in the estimation of blood loss and management of surgical sponges.

    The Pixel 3 System is intended to be used with surgical sponges, software, hardware and accessory devices which have been validated for use with the Pixel 3 System to estimate the hemoglobin (Hb) mass contained on used surgical sponges. The Pixel 3 System is also intended to calculate an estimate of blood volume on used surgical sponges from the estimated Hb mass and a user-entered patient serum Hb value. The validated surgical sponges, hardware, software, accessory devices and Hb mass ranges are listed in the Instructions for Use.

    The Pixel 3 System is also indicated for use to aid in counting surgical sponges and may be used to record and display case-specific blood components infused over time. The Pixel 3 System is additionally indicated for use to aid in managing surgical sponges, including providing a visual record of sponge images, and to record the user-entered weight of used surgical sponges in order to calculate an estimate of fluid volume on the sponges.

    Device Description

    The Pixel 3 System is a software program (mobile medical application) used on an Apple iPad® tablet to capture images of used surgical sponges to assist surgical personnel in the management of surgical sponges after surgical use and to aid in the estimation of blood loss. The main functions of the device are summarized below.

    The Pixel 3 System provides an estimate of the Hb mass lost onto the sponge (sHbL), which is derived from a software algorithm that analyzes images of sponges sent to the Gauss off-site server along with user-entered information about the type of sponge. An estimate of the cumulative blood volume lost onto the sponges (sEBL) is subsequently calculated by dividing the sHbL for each sponge by a user-entered value for the patient's laboratory-derived serum Hb level at the time of image capture. Whereas sHbL is estimated independently from the laboratory-derived serum Hb (i.e., directly from each image), sEBL is derived from a calculator whose inputs are adjustable by the user. The Pixel 3 System provides this estimate of blood content on sponges (i.e., sEBL by sHbL method) and estimate of sHbL only for the validated laparotomy sponge types listed in Table 1.

    The Pixel 3 System may also be used to track the weight of soaked surgical sponges recorded by the user. The device may aid in the estimation of blood loss by calculating an estimate of the cumulative sEBL by weight, provided that a dry and wet weight has been entered for each sponge. This estimate (i.e., sEBL by weight method) is based on the total weight of the soaked sponges less their dry weights normalized by the density of whole blood (1.060 g/mL). For the sEBL by weight method, a user may manually enter sponge types other than those validated for the sEBL by sHbL method (see Table 1 above); however, those sponge types can only be used to calculate sEBL by weight.

    The Pixel 3 System also allows surgical personnel to categorize sponges by sponge type and provides an automated ongoing count of the total number of sponge images and sponge images by tag. The device allows for the input and display of case-specific values pertaining to fluid management during surgical procedures (e.g., packed red blood cell volume administered over time, fresh frozen plasma volume administered over time, platelet volume administered over time), as detailed in the Instructions for Use. The Pixel 3 System also provides a visual record of images for further evaluation during the surgical case.

    To use the device, the user mounts the iPad tablet onto an IV pole; the device contains alignment indicators to help the user align the IV pole. The user then places a sponge in view of the iPad camera (the device contains a camera-bounding box to help the user with sponge placement), and scans an image of the sponge by touching the iPad screen or using an optional wireless foot pedal. The device also contains an ambient light indicator, which helps the user determine when a poor (indicator is yellow) or appropriate (indicator is white) level of ambient light is present for image capture.

    The full-screen display of sHbL and sEBL by sHbL outputs includes an estimate of the cumulative error of the Pixel 3 System, computed as the 95% Bland-Altman Limits of Agreement (and denoted as "95% limits Bland Altman" on the display). The display of estimated error is updated on a real-time basis, as successive sponges are accumulated and scanned. A Bland-Altman plot in biostatistics is a method of data plotting used to analyze the agreement between two different assays. Bias is defined as the arithmetic mean of the differences between the device's output value and measurements obtained using a reference standard. The Bland- Altman Limits of Agreement represent two standard deviations (1.96 x SD) of the differences around the bias, and represent the error range within which 95% of all differences between the device's output and the reference standard's measures are expected to lie.

    AI/ML Overview

    Here's a summary of the acceptance criteria and the study that proves the Pixel 3 System meets them, based on the provided document:

    Acceptance Criteria and Device Performance

    Acceptance Criteria (Special Controls)Reported Device Performance and Compliance
    1. Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use, with comparison to a scientifically valid alternative method for measuring deposited hemoglobin mass. These include lighting, Hb concentrations, blood volume absorption, and presence of non-sanguineous fluids.Bench Testing: The Pixel 3 System demonstrated a strong positive linear correlation (r = 0.92 [95% CI 0.91 to 0.93]) with the reference method (pre-measured Hb mass). The Hb mass bias was 0.01 g Hb with limits of agreement of approximately ± 1.2 g per sponge. It was tested across different sponge types, Hb concentrations (5-17 g/dl), fluid and blood volumes, and various ambient light conditions. The pre-determined acceptance criterion was (b)(4) Trade Secrete/CCI per sponge.
    2. Human factors testing and analysis must validate that the device design and labeling are sufficient for appropriate use by intended users.Human Factors Testing (SW 02089): Evaluated usability with registered nurses (circulating nurses). All 8 users in simulated cases successfully completed tasks. 94% of tasks completed on the first pass, 100% on the second. Likert scores for usability were high (average 4.57). No users identified safety issues.
    3. Appropriate analysis and non-clinical testing must validate the electromagnetic compatibility (EMC) and wireless performance of the device.EMC and Wireless Technology Testing: Compliant with IEC 60601-1-2:2007 (Class B) for EMC. Maintained essential wireless functionality (capturing sponge image and receiving sHbL within one minute) under various noisy wireless environments (single/multiple WiFi, Bluetooth, RFID interferers, maximum power).
    4. Appropriate software verification, validation and hazard analysis must be performed.Software Documentation: Adequately described software development, hazard analysis, and validation/verification activities. System-level test protocols, pass/fail criteria, and results were provided. Cybersecurity issues and mitigation were addressed.
    5. Software display must include an estimate of the cumulative error associated with estimated blood loss values.Device Description: The full-screen display of sHbL and sEBL outputs includes an estimate of the cumulative error, computed as the 95% Bland-Altman Limits of Agreement. This display is updated in real-time.
    6. Labeling must include warnings, cautions, limitations, performance testing summary, validated materials, and EMC/wireless instructions.Labeling: Provided with required warnings, cautions, and limitations (e.g., MR Unsafe, not a sterile device, not to be used as a trigger for clinical action). Includes a detailed summary of performance testing (bias, variance), validated surgical materials (sponge types), and EMC/wireless instructions.

    Study Details

    1. Sample sizes used for the test set and data provenance:

    • Bench Testing:

      • Test Set (sponges): 50 sponges of each of the four validated types (NovaPlus, AMD Ritmed, RFDetect Premium, Allegiance Disposable).
      • Total Scans: (b)(4) Trade Secret/CCI scans per sponge type. The exact total number of sponges in the test set isn't explicitly stated as a single number but would be 50 sponges/type * 4 types = 200 sponges. Each sponge was scanned multiple times.
      • Data Provenance: Not explicitly stated, but likely laboratory-controlled settings (simulated blood loss).
    • Human Factors Testing:

      • Subjects: Registered nurses (circulating nurses).
      • Test Set: (b)(4) Trade Secret/CCI live surgical case evaluations and 8 simulated task-based evaluations.
      • Data Provenance: Single-center study (location not specified), prospective.
    • Preliminary Clinical Testing (Study 1):

      • Patients: 46 patients
      • Sponges: 758 laparotomy sponges ([b]4] Trade Secret/CCI, RFDetect, and AMD Ritmed).
        • 167 sponges analyzed on a per-sponge basis.
        • 591 sponges analyzed in batches.
      • Data Provenance: Prospective, multi-center (3 clinical sites, location not specified). Conducted between July and November 2012.
    • Confirmatory Clinical Testing (Study 2):

      • Patients: 50 patients
      • Sponges: 791 laparotomy sponges (RFDetect laparotomy sponges). All individually assayed.
      • Data Provenance: Prospective, single-center (1 clinical site, location not specified). Enrollment from July 2013 to October 2013.

    2. Number of experts used to establish the ground truth for the test set and their qualifications:

    • Bench Testing: The ground truth was established by pre-measured Hb mass deposited in controlled amounts. No human experts were used for this ground truth as it was a direct measurement.
    • Clinical Studies (Study 1 & 2): The ground truth for Hb mass was established using a "mechanical extraction method (assay sHbL)" or "rinsing and photometric assay of the effluent (reference method)." This indicates a laboratory method rather than expert human interpretation.

    3. Adjudication method for the test set:

    • Bench Testing: Not applicable, as ground truth was direct measurement.
    • Clinical Studies (Study 1 & 2): Not applicable, as ground truth was established by a laboratory reference method.

    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

    • A formal MRMC study comparing AI-assisted human readers to unassisted human readers was not explicitly described in the provided text.
    • However, the Confirmatory Clinical Testing (Study 2) did compare the Pixel 3 System's performance (sEBL) to traditional human methods:
      • Visual (single-rater) estimates by the anesthesiologist.
      • Gravimetric (weighing sponges) methods.
    • Effect Size (Comparison to traditional methods): In Study 2, the Pixel 3 System's sEBL (end of case) displayed a consistently lower variance and higher precision than both visual estimates and gravimetric methods. The gravimetric method overestimated blood loss by 359 ml per patient compared to the Pixel 3 System in Study 1. This suggests significant improvement in accuracy and precision over traditional human-driven methods.

    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

    • Yes, the Bench Testing was a standalone evaluation of the algorithm's accuracy in estimating Hb mass compared to a pre-measured reference.
    • The Clinical Studies (Study 1 and 2) also evaluated the Pixel 3 System's output (sHbL and sEBL) as a standalone estimate compared to the laboratory reference method, noting its bias and correlation. While users were present to scan, the performance metrics (bias, correlation, limits of agreement) directly reflect the algorithm's output against the ground truth.

    6. The type of ground truth used:

    • Bench Testing: Direct measurement of pre-deposited Hb mass on sponges.
    • Clinical Studies (Study 1 & 2): Laboratory-based reference method involving "mechanical extraction" or "rinsing and photometric assay of the effluent" to measure Hb mass. This is a highly objective, quantifiable ground truth.

    7. The sample size for the training set:

    • The document does not explicitly state the sample size for the training set. It focuses on the validation studies.

    8. How the ground truth for the training set was established:

    • Since the training set size and details are not provided, information on how its ground truth was established is also not available in the given text. However, given the methodology of the test sets, it is highly probable that similar laboratory-based reference methods would have been used for training data ground truth.
    Ask a Question

    Ask a specific question about this device

    K Number
    K121274
    Device Name
    PIXEL APP
    Date Cleared
    2012-06-27

    (61 days)

    Product Code
    Regulation Number
    880.2740
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Applicant Name (Manufacturer) :

    GAUSS SURGICAL, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Gauss Pixel App is intended to be used to aid current clinical practices in recording the number of surgical sponges and for visibility for assessment of sponge images.

    Device Description

    Not Found

    AI/ML Overview

    I am sorry I cannot fulfill your request to describe the acceptance criteria and study proving device efficacy based on the provided document. The document primarily consists of a 510(k) clearance letter from the FDA, an "Indications for Use" form, and general regulatory information. It does not contain the specific details about the acceptance criteria, study design, results, or data provenance you are asking for.

    The information provided only states that the device is "substantially equivalent" to legally marketed predicate devices, which is the basis for 510(k) clearance. It does not include the detailed performance testing data that would be part of a full study report.

    Ask a Question

    Ask a specific question about this device

    K Number
    K120473
    Device Name
    PIXEL APP
    Date Cleared
    2012-04-09

    (53 days)

    Product Code
    Regulation Number
    880.2740
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    GAUSS SURGICAL, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Gauss Pixel App is indicated for use to aid current practices in recording the number of surgical sponges and for visibility for assessment of sponge images.

    Device Description

    The Gauss Pixel App is a software program used on an iPad tablet to capture images of sponges to assist surgical personnel in the management of surgical sponges after surgical The App allows surgical personnel to categorize sponges by sponge type and use. provides an automated ongoing count of total sponge images and sponge images by tag. It also provides a visual record of images for further evaluation. This program is not intended to replace existing sponge counting practices and sponges should be retained per the user's standard sponge management practice until the case is complete and sponge counting has been finalized.

    AI/ML Overview

    Here's a summary of the acceptance criteria and study findings for the Gauss Pixel App, based on the provided document:

    1. Acceptance Criteria and Reported Device Performance

    Acceptance CriteriaReported Device Performance (Gauss Pixel App)
    Record Images as Indicated by UserConfirmed: The application provided instructions for use and recorded images as indicated by the user.
    Accurately Tag Images as Indicated by UserConfirmed: The application accurately tagged images as indicated by the user.
    Accurately Provide Automated Counting (Total)Confirmed: The application accurately provided automated counting both in total.
    Accurately Provide Automated Counting (by Type)Confirmed: The application accurately provided automated counting by type.
    Allow Visual Review and Management of ImagesConfirmed: The application allowed visual review and management (re-tagging, deletion) of all images as appropriate.
    Function as IntendedDemonstrated: Results of performance testing through the software verification and validation process demonstrate that the Gauss Pixel App functions as intended.
    Substantial Equivalence to Predicate DeviceDemonstrated: The Gauss Pixel App is as safe and effective as the predicate, has the same intended uses and indications, and utilizes a new technological method (software) which complements current clinical practices and does not raise new issues of safety or effectiveness. Software verification and validation demonstrate it functions as intended.

    2. Sample Size and Data Provenance

    The document does not explicitly state the sample size used for a test set in the conventional sense of a clinical trial or independent validation. The performance claims are based on "software verification and validation testing." This typically involves internal testing by the developer to ensure the software meets its specified functional and non-functional requirements.

    There is no information provided regarding the country of origin of data or whether it was retrospective or prospective. Given the nature of a 510(k) submission for a Class I device and the focus described (software verification and validation), it's highly probable that this involved internal testing rather than a large-scale clinical study with external patient data.

    3. Number of Experts and Qualifications

    The document does not specify the number of experts, their qualifications, or their role in establishing a "ground truth" for a test set. The validation described is primarily around the software's functional performance (e.g., counting, tagging, image display) rather than assessing clinical accuracy against expert opinion in a diagnostic context.

    4. Adjudication Method

    No adjudication method (e.g., 2+1, 3+1) is mentioned, as the described validation focuses on software functionality rather than interpreting findings against a 'ground truth' that would require expert consensus.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    No MRMC comparative effectiveness study is mentioned. The device is described as an adjunctive tool to aid current practices, not as a replacement or independent diagnostic tool. The focus is on verifying its own functionality (counting, image display) rather than its impact on human reader performance. Therefore, an effect size of human readers improving with/without AI assistance is not reported.

    6. Standalone Performance

    Yes, a standalone (algorithm only without human-in-the-loop performance) assessment was done for the core functionalities of the application. The document states: "Results of performance testing confirmed that the application provided instructions for use, recorded images as indicated by the user, accurately tagged images as indicated by the user, accurately provided automated counting both in total and by type and allowed visual review and management (re-tagging, deletion) of all images as appropriate." This describes the independent functional performance of the software.

    7. Type of Ground Truth Used

    For the described performance testing, the "ground truth" appears to be the expected functional behavior of the software as defined by its specifications and design. For example:

    • For "accurately provided automated counting," the ground truth would be the actual number of images taken and the actual type assigned by a user, against which the software's automated count is compared.
    • For "accurately tagged images," the ground truth is the tag the user intended to apply, against which the software's recorded tag is compared.

    It does not refer to medical ground truth like pathology, outcomes data, or expert consensus on a diagnostic interpretation.

    8. Sample Size for the Training Set

    The document does not specify a sample size for a training set. This is consistent with the nature of the device as a functional tool for managing sponges, not a machine learning model that requires a large training dataset to develop its core functionality (like image recognition for diagnostic purposes). The "training" described implicitly refers to the software development and testing cycles designed to ensure correct functionality.

    9. How Ground Truth for the Training Set Was Established

    Given the information provided, the concept of a "ground truth for the training set" as it pertains to typical AI/ML development (e.g., labeled data for model training) is not applicable here. The ground truth for the development and verification of the software's core functions (counting, tagging) would have been established by the software's design specifications and the expected, correct outputs for given inputs during testing. This is standard software engineering practice rather than a data-driven ground truth for a machine learning algorithm.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1